Carfilzomib

CAS 868540-17-4
Back to the Catalog Contact us about this API

General Information

Carfilzomib is indicated for relapsed or refractory multiple myeloma in adults who have received 1-3 lines of therapy in combination with dexamethasone, lenalidomide plus dexamethasone, or daratumumab plus dexamethasone.

About the API

Trade name(s) Kyprolis
Technology Peptide
Therapeutic category Oncology
Available formulations Injectables
Regulations US DMF Flag US DMF

Updates about Carfilzomib

  • Jan 31, 2016 New US DMF dated 01/2016 is available.

Related API products

Bleomycin sulfate 9041-93-4 Imatinib Mesylate 220127-57-1 Nilotinib Fumarate 1304125-88-9 Midostaurin 120685-11-2

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.

For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.

This site uses cookies (unless you have disabled them) to give you a better and personalized browsing experience and targeted ads.
By continuing your visit on this website, you agree to the use of Cookies on your device. Find out more in our Privacy Policy